Skip to main content
FERMENTA BIOTECH LIMITED logo

FERMENTA BIOTECH LIMITED — Investor Relations & Filings

Ticker · FERMENTA ISIN · INE225B01021 LEI · 335800VNTNWW8G1U9314 BSE.NS Manufacturing
Open in API
Filings indexed 671 across all filing types
Latest filing 2022-05-30 Regulatory Filings
Country IN India
Listing BSE.NS FERMENTA

About FERMENTA BIOTECH LIMITED

https://fermentabiotech.com

Fermenta Biotech Limited is a specialized biotechnology company primarily focused on the development and manufacture of Vitamin D3 (Cholecalciferol). As one of the few vertically integrated manufacturers globally, the company produces Vitamin D3 for diverse applications, including pharmaceuticals, dietary supplements, human nutrition, and animal feed. Beyond its core Vitamin D3 portfolio, the company offers a range of specialty enzymes, particularly for the synthesis of beta-lactam antibiotics, and provides environmental solutions through its biotechnology expertise. Fermenta Biotech emphasizes high-quality standards, maintaining various international certifications for its manufacturing facilities. Its product offerings extend to premixes and value-added formats designed to meet specific formulation requirements. The company serves a global clientele, leveraging its research and development capabilities to innovate in the fields of nutrition and biotechnology.

Recent filings

Filing Released Lang Actions
We write to inform you that the Board of Directors of the Company at its meeting held on May 30, 2022 has, inter alia: 1. Approved the Audited Financial Results (Standalone and Consolidated) ....
Regulatory Filings
2022-05-30 English
We write to inform you that the Board of Directors of the Company at its meeting held on May 30, 2022 has, inter alia: 1. Approved the Audited Financial Results (Standalone and ....
Regulatory Filings
2022-05-30 English
Fermenta Biotech Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled to be heldon May 30, 2022, inter alia:1. To consider and approve ....
Regulatory Filings Classification · 95% confidence The document is a notice from the company to the stock exchange about an upcoming Board Meeting scheduled for May 30, 2022. The notice mentions the agenda items including consideration and approval of audited financial results for the quarter and financial year ended March 31, 2022, and recommendation of final equity dividend. It also informs about the closure of the trading window in compliance with SEBI regulations. The document is a formal announcement of a Board Meeting and related compliance matters, not the actual financial results or report. It is short (2326 characters) and serves as a notification rather than a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such regulatory announcements that do not fit other specific categories.
2022-05-23 English
The meeting of the Board of Directors of the Company is scheduled to be held on Monday, May 30, 2022, inter alia: (i) to consider and approve the audited financial results of the Company ....
Regulatory Filings Classification · 95% confidence The document is a notice from the company to the stock exchange about an upcoming Board Meeting scheduled for May 30, 2022. The notice mentions the agenda to consider and approve audited financial results for the quarter and financial year ended March 31, 2022, and to consider recommending a final equity dividend. It also informs about the closure of the trading window in compliance with SEBI regulations. The document does not contain any financial data or results itself, but rather announces the meeting and trading window closure. The document length is short (2326 characters) and it serves as an announcement rather than a report. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance notice.
2022-05-23 English
Fermenta Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2022 ,inter alia, to consider and approve Pursuant to Regulation 29 ....
Regulatory Filings Classification · 95% confidence The document is a notice of a Board Meeting scheduled to consider and approve audited financial results and dividend recommendation. It also informs about the closure of the trading window as per SEBI regulations. The document is short (2326 characters) and serves as an announcement rather than containing actual financial data or the report itself. It does not contain financial statements or detailed analysis, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a certification or insider dealing report. The document is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement informing the stock exchange and public about the board meeting and trading window closure, which is a compliance disclosure under SEBI regulations.
2022-05-23 English
Pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith copy of the newspaper publication regarding dispatch of ....
Regulatory Filings
2022-05-13 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.